Øjenlidelser Post- marketing- rapporter har beskrevet nye tilfælde samt forværring af diabetisk maculaødem med synsforstyrrelser hos patienter i behandling med thiazolider, herunder rosiglitazon.
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including rosiglitazone.